BioPharmSignal logoBioPharmSignal

Biotech News

Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026

Adaptive Biotechnologies (ADPT)Adaptive BiotechnologiesEarnings

SEATTLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial

Related news

CVRXCVRx2026-10-22 20:30 EST

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026

SGHTSight Sciences2026-10-21 20:05 EST

Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

OMOutset Medical2026-10-21 20:05 EST

Outset Medical to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

RXSTRxSight2026-10-20 20:05 EST

RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3

STXSStereotaxis2026-10-20 11:40 EST

Stereotaxis to Report Third Quarter 2026 Financial Results on November 10, 2026

IRTCiRhythm2026-10-15 20:05 EST

iRhythm Holdings to Report Third Quarter 2026 Financial Results on November 5, 2026

PRCTPROCEPT BioRobotics2026-10-12 20:05 EST

PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026

PLSEPulse Biosciences2026-10-22 20:05 EST

Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026

TCMDTactile Systems Technology, Inc.2026-10-19 20:05 EST

Tactile Medical to Release Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026

HYPRHyperfine2026-10-08 11:30 EST

Hyperfine, Inc. to Announce Third Quarter 2026 Financial Results on November 9, 2026

View all latest news

Adaptive Biotechnologies

Adaptive Immune-System Platform Adaptive Biotechnologies develops clinical products by decoding the genetics of the adaptive immune system. Its proprietary platform measures immune-receptor sequences at scale to support disease monitoring, drug development and the discovery of immune-based therapeutics. Minimal Residual Disease The...

Recent company news

ADPTAdaptive Biotechnologies2026-10-14 20:05 EST

Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026

ADPTAdaptive Biotechnologies2026-09-25 12:03 EST

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

ADPTAdaptive Biotechnologies2026-09-17 12:00 EST

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

ADPTAdaptive Biotechnologies2026-09-01 20:05 EST

Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

ADPTAdaptive Biotechnologies2026-07-29 20:05 EST

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

Stock data

Close
25.33 USD
Market cap
2.42B USD
Exchange
NASDAQ
Sector
MedTech
Location
United States